Table II.

Statistical Evaluation of the ADAS-Cog Value Distribution at Week 14 of the Observed and Simulated Phase IIb Data

	Placebo		0.25 mg		0.5 mg		1 mg
	OBS	SIM	OBS	SIM	OBS	SIM	OBS	SIM
N	71	1,000	83	1,000	66	1,000	56	1,000
P1	−22.33	−14.23	−12.67	−14.93	−15.00	−17.29	−13.67	−16.06
P5	−11.67	−4.99	−8.67	−8.80	−11.33	−9.16	−10.67	−9.78
P10	−8.67	−3.30	−7.33	−6.55	−10.00	−6.53	−8.33	−6.71
P25	−5.33	−1.34	−4.67	−3.72	−4.33	−3.71	−4.33	−3.75
Median	−1.67	0.58	−1.67	−1.47	−1.17	−1.30	−2.00	−1.39
Mean	−1.94	0.08	−1.55	−1.99	−1.70	−2.04	−0.98	−1.99
P75	1.33	2.37	1.33	0.57	2.00	0.59	1.67	0.61
P95	6.67	4.68	6.00	3.23	6.00	3.31	11.33	3.35
P99	13.67	6.13	13.00	5.64	7.67	5.06	17.67	5.47

OBS observed; SIM simulated